SEVIDENT, INC.

Medtech · Defunct

A fluorescent immunoassay diagnostic tool (ViCAP-DENV FIA) using novel paramagnetic microparticle capture technology for rapid point-of-care detection of dengue virus in blood samples

Grants
$278K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
$299K
1 award · Health and Human S
#423 of 4531 in medtech
Patents
4
2 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a novel test for the early detection of Dengue Virus infection$277,652
Federal contractDepartment of Health and Human Services · Igf::ot::igf Sevident, INC.:1242717 [16-064431] SBIR Phase I Topic$299,338
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
420LIFETIME OMICS, INC.$300K—
421ESPER BIOSCIENCES INC$300K—
422DARWIN BIOSCIENCES, INC.$299K—
423SEVIDENT, INC.$299K—
424SALUS DISCOVERY LLC$299K—
425Focal Medical, Inc.$298K$6.4M
426MGENUITY CORPORATION$296K—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 2 granted of 4

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.